Novo Nordisk A S (NVO) reported $46.8B in revenue for fiscal 2025, +11.0% year on year. That ranks #113 by revenue among 2853 SEC filers and #18 in Healthcare. Net income was $15.5B, a net margin of 33.1%. Revenue has grown 11.3% a year on average since 2015 ($16.1B then). The fiscal 2025 balance sheet shows $85.4B in total assets, $4.2B in cash and $18.7B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueDKK 309B | $46.8B | +11.0% | FY20252025-12-31 |
| Gross profitDKK 250B | $37.9B | +6.2% | FY20252025-12-31 |
| Operating incomeDKK 128B | $19.3B | +3.8% | FY20252025-12-31 |
| Net incomeDKK 102B | $15.5B | +5.8% | FY20252025-12-31 |
| Operating cash flowDKK 119B | $18.0B | +2.7% | FY20252025-12-31 |
| Capital expenditureDKK 60.1B | $9.1B | +33.0% | FY20252025-12-31 |
| Total assetsDKK 543B | $85.4B | +31.7% | FY20252025-12-31 |
| Shareholders' equityDKK 194B | $30.5B | +52.7% | FY20252025-12-31 |
| CashDKK 26.5B | $4.2B | +90.9% | FY20252025-12-31 |
| Long-term debtDKK 119B | $18.7B | +49.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Figures are reported under IFRS in DKK and converted to US dollars at ECB reference rates — fiscal 2025 average 6.605 DKK/$ for income items, year-end 6.357 DKK/$ for balance-sheet items.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 6 of 161 companies compared | 33.1% | |
| Operating marginRank 4 of 160 companies compared | 41.3% | |
| R&D as share of revenueRank 33 of 102 companies compared | 16.8% | |
| Cash as share of revenueRank 96 of 160 companies compared | 8.9% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Novo Nordisk A S
- Ticker
- NVO
- Exchange
- NYSE
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000353278
Filings
- 20-FFeb 4, 2026Open filing →
- 20-FFeb 5, 2025Open filing →
- 20-FJan 31, 2024Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| AbbVieABBV | $61.2B | $4.2B |
| AstraZenecaAZN | $58.7B | $10.2B |
| Bristol Myers SquibbBMY | $48.2B | $7.1B |
| Novo Nordisk A SNVO | $46.8B | $15.5B |
| Molina HealthcareMOH | $45.4B | $472M |
| Abbott LaboratoriesABT | $44.3B | $6.5B |
| GSKGSK | $43.1B | $7.5B |
Novo Nordisk A S compared withBristol Myers SquibbMolina Healthcare
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Novo Nordisk A S — Key figures |url=https://companiesranked.com/en/company/novo-nordisk-a-s |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Novo Nordisk A S — Key figures. CompaniesRanked. https://companiesranked.com/en/company/novo-nordisk-a-sBibTeX
@misc{companiesranked-en-company-novo-nordisk-a-s-2026,
author = {{CompaniesRanked}},
title = {{Novo Nordisk A S — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/novo-nordisk-a-s}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0000353278-26-000012 · February 4, 2026
{{cite web |title=Novo Nordisk A S — Key figures — 20-F (0000353278-26-000012) |url=https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-04}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.